Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Verrica Pharmaceuticals ( (VRCA) ).
On June 27, 2025, Verrica Pharmaceuticals amended its collaboration with Torii Pharmaceutical to initiate a global Phase 3 clinical trial for YCANTH® to treat common warts. Torii will provide an $8 million milestone payment and fund the first $40 million of the trial costs. The amendment also includes a $10 million payment if YCANTH is approved for molluscum contagiosum in Japan. This strategic move aims to expand YCANTH’s market presence and strengthen Verrica’s financial position, with the first patient dosing expected in the fourth quarter of 2025.
The most recent analyst rating on (VRCA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Verrica Pharmaceuticals stock, see the VRCA Stock Forecast page.
Spark’s Take on VRCA Stock
According to Spark, TipRanks’ AI Analyst, VRCA is a Neutral.
Verrica Pharmaceuticals’ overall stock score is constrained by severe financial challenges, including persistent losses and negative equity. Technical indicators offer little support, and valuation metrics are unfavorable due to negative earnings. Corporate events provide a slight positive, but significant risks remain.
To see Spark’s full report on VRCA stock, click here.
More about Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases requiring medical interventions. Its primary product, YCANTH® (VP-102), is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting millions in the United States, primarily children. Verrica is also working on expanding YCANTH’s use to treat common warts and has a licensing agreement with Lytix Biopharma AS for developing treatments for non-melanoma skin cancers.
Average Trading Volume: 356,451
Technical Sentiment Signal: Sell
Current Market Cap: $48.34M
For an in-depth examination of VRCA stock, go to TipRanks’ Overview page.